{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:51:51Z","timestamp":1789980711112,"version":"4.0.1"},"reference-count":102,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1038\/jid.2014.522","type":"journal-article","created":{"date-parts":[[2015,1,22]],"date-time":"2015-01-22T09:36:02Z","timestamp":1421919362000},"page":"1234-1243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["Placebo Effects on Itch: A Meta-Analysis of Clinical Trials of Patients with Dermatological Conditions"],"prefix":"10.1016","volume":"135","author":[{"given":"Antoinette I.M.","family":"van Laarhoven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ineke M.","family":"van der Sman-Mauriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Rogier T.","family":"Donders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde C.","family":"Pronk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.M.","family":"van de Kerkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea W.M.","family":"Evers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/jid.2014.522_bb0010","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/(SICI)1098-2299(199804)43:4<185::AID-DDR1>3.0.CO;2-E","volume":"43","author":"Abu Shereeah","year":"1998","journal-title":"Drug Dev Res"},{"key":"10.1038\/jid.2014.522_bb0015","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/ije\/dyh299","article-title":"Regression to the mean: what it is and how to deal with it","volume":"34","author":"Barnett","year":"2005","journal-title":"Int J Epidemiol"},{"key":"10.1038\/jid.2014.522_bb0020","doi-asserted-by":"crossref","first-page":"e91727","DOI":"10.1371\/journal.pone.0091727","article-title":"Role of conditioning and verbal suggestion in placebo and nocebo effects on itch","volume":"9","author":"Bartels","year":"2014","journal-title":"PLoS One"},{"key":"10.1038\/jid.2014.522_bb0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1146\/annurev.pharmtox.48.113006.094711","article-title":"Mechanisms of placebo and placebo-related effects across diseases and treatments","volume":"48","author":"Benedetti","year":"2008","journal-title":"Annu Rev Pharmaco Toxicol"},{"key":"10.1038\/jid.2014.522_bb0030","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0091-6749(86)90319-2","article-title":"Efficacy and safety of astemizole, a long-acting and nonsedating H1 antagonist for the treatment of chronic idiopathic urticaria","volume":"77","author":"Bernstein","year":"1986","journal-title":"J Allergy Clin Immunol"},{"key":"10.1038\/jid.2014.522_bb0035","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1365-2133.1989.tb08196.x","article-title":"Failure of terfenadine in relieving the pruritus of atopic dermatitis","volume":"121","author":"Berth-Jones","year":"1989","journal-title":"Br J Dermatol"},{"key":"10.1038\/jid.2014.522_bb0040","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2133.1990.tb14733.x","article-title":"Failure of papaverine to reduce pruritus in atopic dermatitis: a double-blind, placebo-controlled cross-over study","volume":"122","author":"Berth-Jones","year":"1990","journal-title":"Br J Dermatol"},{"key":"10.1038\/jid.2014.522_bb0045","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1046\/j.1365-2133.2002.04989.x","article-title":"Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial","volume":"147","author":"Berth-Jones","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1038\/jid.2014.522_bb0050","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jaad.2005.10.061","article-title":"A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis","volume":"54","author":"Bissonnette","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1038\/jid.2014.522_bb0055","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/0190-9622(95)90233-3","article-title":"Cetirizine and astemizole therapy for chronic idiopathic urticaria: a double-blind, placebo-controlled, comparative trial","volume":"33","author":"Breneman","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1038\/jid.2014.522_bb0060","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/0091-6749(89)90011-0","article-title":"Therapy of chronic idiopathic urticaria with nifedipine: demonstration of beneficial effect in a double-blinded, placebo-controlled, crossover trial","volume":"83","author":"Bressler","year":"1989","journal-title":"J Allergy Clin Immunol"},{"key":"10.1038\/jid.2014.522_bb0065","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1398-9995.1996.tb00092.x","article-title":"Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria","volume":"51","author":"Brostoff","year":"1996","journal-title":"Allergy"},{"key":"10.1038\/jid.2014.522_bb0070","article-title":"The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib","author":"Bushmakin","year":"2013","journal-title":"J Dermatol Treat"},{"key":"10.1038\/jid.2014.522_bb0075","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000056337","article-title":"Azelastine tablets in the treatment of chronic idiopathic urticaria. Phase iii, randomised, double-blind, placebo and active controlled multicentric clinical trial","volume":"14","author":"Camarasa","year":"2001","journal-title":"Skin Pharmacol Appl Skin Physiol"},{"key":"10.1038\/jid.2014.522_bb0080","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.pain.2013.02.002","article-title":"Placebo analgesia: psychological and neurobiological mechanisms","volume":"154","author":"Colloca","year":"2013","journal-title":"Pain"},{"key":"10.1038\/jid.2014.522_bb0085","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1098\/rstb.2010.0398","article-title":"How placebo responses are formed: a learning perspective","volume":"366","author":"Colloca","year":"2011","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1038\/jid.2014.522_bb0090","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jaci.2004.06.018","article-title":"Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria","volume":"114","author":"Di Lorenzo","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1038\/jid.2014.522_bb0095","first-page":"16","article-title":"Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study","volume":"12","author":"Dubertret","year":"1999","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1038\/jid.2014.522_bb0100","first-page":"223","article-title":"Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study","volume":"17","author":"Dubertret","year":"2007","journal-title":"Eur J Dermatol"},{"key":"10.1038\/jid.2014.522_bb0105","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.pain.2009.08.019","article-title":"Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations","volume":"146","author":"Dworkin","year":"2009","journal-title":"Pain"},{"key":"10.1038\/jid.2014.522_bb0110","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1046\/j.1365-2133.1998.02174.x","article-title":"Effects of nitrazepam on nocturnal scratching in adults with atopic dermatitis: a double-blind placebo-controlled crossover study","volume":"138","author":"Ebata","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1038\/jid.2014.522_bb0115","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies","volume":"71","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1038\/jid.2014.522_bb0120","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.jaad.2005.06.053","article-title":"Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial","volume":"53","author":"Feldman","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1038\/jid.2014.522_bb0125","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1365-2125.1985.tb05122.x","article-title":"Terfenadine and placebo compared in the treatment of chronic idiopathic urticaria: a randomised double-blind study","volume":"20","author":"Ferguson","year":"1985","journal-title":"Br J Clin Pharmacol"},{"key":"10.1038\/jid.2014.522_bb0130","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0091-6749(99)70091-6","article-title":"A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria","volume":"104","author":"Finn","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"10.1038\/jid.2014.522_bb0135","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/0091-6749(86)90266-6","article-title":"The treatment of mild to severe chronic idiopathic urticaria with astemizole: double-blind and open trials","volume":"78","author":"Fox","year":"1986","journal-title":"J Allergy Clin Immunol"},{"key":"10.1038\/jid.2014.522_bb0140","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1111\/j.1365-2222.2007.02811.x","article-title":"A double-blind, placebo-controlled trial of montelukast in adult atopic eczema","volume":"37","author":"Friedmann","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"10.1038\/jid.2014.522_bb0145","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/BF00412560","article-title":"A double blind trial of H1 and H2 receptor antagonists in the treatment of atopic dermatitis","volume":"276","author":"Frosch","year":"1984","journal-title":"Arch Dermatol Res"},{"key":"10.1038\/jid.2014.522_bb0150","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000249599","article-title":"An assessment of the novel antihistamine BW 825C in the treatment of chronic idiopathic urticaria. A placebo-controlled study","volume":"169","author":"Gibson","year":"1984","journal-title":"Dermatologica"},{"key":"10.1038\/jid.2014.522_bb0155","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1398-9995.2007.01330.x","article-title":"Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicentre study","volume":"62","author":"Gimenez-Arnau","year":"2007","journal-title":"Allergy"},{"key":"10.1038\/jid.2014.522_bb0160","first-page":"328","article-title":"Cetirizine vs placebo in chronic idiopathic urticaria\u2014a double blind randomised cross-over study","volume":"20","author":"Goh","year":"1991","journal-title":"Ann Acad Med Singapore"},{"key":"10.1038\/jid.2014.522_bb0165","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/bjd.12636","article-title":"Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: Use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory","volume":"170","author":"Gordon","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1038\/jid.2014.522_bb0170","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1001\/jama.290.23.3073","article-title":"Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial","volume":"290","author":"Gordon","year":"2003","journal-title":"JAMA"},{"key":"10.1038\/jid.2014.522_bb0175","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaci.2011.01.053","article-title":"Contrasting pathogenesis of atopic dermatitis and psoriasis\u2014part I: clinical and pathologic concepts","volume":"127","author":"Guttman-Yassky","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1038\/jid.2014.522_bb0180","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.pain.2011.01.050","article-title":"Systematic review: Placebo response in drug trials of fibromyalgia syndrome and painful peripheral diabetic neuropathy-magnitude and patient-related predictors","volume":"152","author":"Hauser","year":"2011","journal-title":"Pain"},{"key":"10.1038\/jid.2014.522_bb0185","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1037\/1082-989X.3.4.486","article-title":"Fixed- and random-effects models in meta-analysis","volume":"3","author":"Hedges","year":"1998","journal-title":"Psychol Methods"},{"key":"10.1038\/jid.2014.522_bb0190","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1398-9995.1998.tb03867.x","article-title":"Differential effects of new-generation H1-receptor antagonists in pruritic dermatoses","volume":"53","author":"Henz","year":"1998","journal-title":"Allergy"},{"key":"10.1038\/jid.2014.522_bb0195","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. The Cochrane Collaboration","year":"2009"},{"key":"10.1038\/jid.2014.522_bb0200","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.pain.2006.06.003","article-title":"Bradykinin is a potent pruritogen in atopic dermatitis: a switch from pain to itch","volume":"126","author":"Hosogi","year":"2006","journal-title":"Pain"},{"key":"10.1038\/jid.2014.522_bb0205","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2796.2004.01355.x","article-title":"Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment","volume":"256","author":"Hrobjartsson","year":"2004","journal-title":"J Intern Med"},{"key":"10.1038\/jid.2014.522_bb0210","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2133.1988.tb07103.x","article-title":"Treatment of chronic urticaria with cetirizine dihydrochloride a non-sedating antihistamine","volume":"119","author":"Juhlin","year":"1988","journal-title":"Br J Dermatol"},{"key":"10.1038\/jid.2014.522_bb0215","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0190-9622(87)70104-2","article-title":"Controlled clinical assessment of astemizole in the treatment of chronic idiopathic urticaria and angioedema","volume":"16","author":"Kailasam","year":"1987","journal-title":"J Am Acad Dermatol"},{"key":"10.1038\/jid.2014.522_bb0220","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0091-6749(05)80246-5","article-title":"Urticaria: clinical efficacy of cetirizine in comparison with hydroxyzine and placebo","volume":"86","author":"Kalivas","year":"1990","journal-title":"J Allergy Clin Immunol"},{"key":"10.1038\/jid.2014.522_bb0225","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","article-title":"Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy","volume":"132","author":"Kaplan","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1038\/jid.2014.522_bb0230","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S1081-1206(10)61325-7","article-title":"Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study","volume":"94","author":"Kaplan","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1038\/jid.2014.522_bb0235","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-4632.2005.02609.x","article-title":"Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, parallel, multicenter study","volume":"45","author":"Kapp","year":"2006","journal-title":"Int J Dermatol"},{"key":"10.1038\/jid.2014.522_bb0240","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1398-9995.1981.tb01877.x","article-title":"Double-blind crossover trial comparing systemic chromosome-carboxylic acid with placebo in patients with atopic dermatitis","volume":"36","author":"Kavli","year":"1981","journal-title":"Allergy"},{"issue":"Suppl 1","key":"10.1038\/jid.2014.522_bb0245","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/S0954-6111(11)70018-X","article-title":"Add-on montelukast in antihistamine-resistant chronic idiopathic urticaria","volume":"105","author":"Kosnik","year":"2011","journal-title":"Respir Med"},{"key":"10.1038\/jid.2014.522_bb0250","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/j.1365-2133.2005.06948.x","article-title":"Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial","volume":"153","author":"Krueger","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1038\/jid.2014.522_bb0255","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","article-title":"Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis","volume":"366","author":"Leonardi","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1038\/jid.2014.522_bb0260","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/0091-6749(90)90079-J","article-title":"Thymopentin therapy reduces the clinical severity of atopic dermatitis","volume":"85","author":"Leung","year":"1990","journal-title":"J Allergy Clin Immunol"},{"key":"10.1038\/jid.2014.522_bb0265","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1034\/j.1398-9995.2001.056006512.x","article-title":"Systemic ketoconazole is an effective treatment of atopic dermatitis with IgE-mediated hypersensitivity to yeasts","volume":"56","author":"Lintu","year":"2001","journal-title":"Allergy"},{"key":"10.1038\/jid.2014.522_bb0270","doi-asserted-by":"crossref","first-page":"e363","DOI":"10.1111\/j.1468-3083.2012.04689.x","article-title":"Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria","volume":"27","author":"Magerl","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1038\/jid.2014.522_bb0275","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/j.1468-3083.2009.03129.x","article-title":"Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study","volume":"23","author":"Malekzad","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1038\/jid.2014.522_bb0280","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/jdv.12081","article-title":"Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis","volume":"28","author":"Mamolo","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1038\/jid.2014.522_bb0285","article-title":"Application of the Itch Severity Score in patients with moderate-to-severe plaque psoriasis: clinically important difference and responder analyses","author":"Mamolo","year":"2014","journal-title":"J Dermatol Treat"},{"key":"10.1038\/jid.2014.522_bb0290","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.anai.2011.09.008","article-title":"Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria","volume":"108","author":"Mathias","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1038\/jid.2014.522_bb0295","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jaci.2011.04.038","article-title":"Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase","volume":"128","author":"Maurer","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1038\/jid.2014.522_bb0300","first-page":"971","article-title":"Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria","volume":"11","author":"Maurer","year":"2013","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1038\/jid.2014.522_bb0305","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1038\/jid.2014.522_bb0310","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(06)68340-2","article-title":"Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial","volume":"367","author":"Meggitt","year":"2006","journal-title":"Lancet"},{"key":"10.1038\/jid.2014.522_bb0315","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaad.2009.03.027","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents","volume":"61","author":"Menter","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1038\/jid.2014.522_bb0320","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jclinepi.2005.12.001","article-title":"The nature and power of the placebo effect","volume":"59","author":"Miller","year":"2006","journal-title":"J Clin Epidemiol"},{"key":"10.1038\/jid.2014.522_bb0325","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1038\/jid.2014.522_bb0330","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1067\/mjd.2003.143","article-title":"Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial","volume":"48","author":"Monroe","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1038\/jid.2014.522_bb0335","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0190-9622(89)80353-6","article-title":"Efficacy and safety of nalmefene in patients with severe pruritus caused by chronic urticaria and atopic dermatitis","volume":"21","author":"Monroe","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1038\/jid.2014.522_bb0340","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1365-2133.1994.tb02936.x","article-title":"Maintenance treatment with cyclosporin in atopic eczema","volume":"130","author":"Munro","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1038\/jid.2014.522_bb0345","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1081-1206(10)62515-X","article-title":"Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria","volume":"84","author":"Nelson","year":"2000","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1038\/jid.2014.522_bb0350","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1398-9995.2005.00791.x","article-title":"Anti-IL-5 recombinant humanized monoclonal antibody","volume":"60","author":"Oldhoff","year":"2005","journal-title":"Allergy"},{"key":"10.1038\/jid.2014.522_bb0355","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-5945-5-13","article-title":"Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]","volume":"5","author":"Ortonne","year":"2005","journal-title":"BMC Dermatol"},{"key":"10.1038\/jid.2014.522_bb0360","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.bbi.2006.05.003","article-title":"Expectations and associations that heal: immunomodulatory placebo effects and its neurobiology","volume":"20","author":"Pacheco-Lopez","year":"2006","journal-title":"Brain Behav Immun"},{"key":"10.1038\/jid.2014.522_bb0365","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1046\/j.1365-2222.2001.01189.x","article-title":"Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and\/or acetylsalicylic acid","volume":"31","author":"Pacor","year":"2001","journal-title":"Clin Exp Allergy"},{"key":"10.1038\/jid.2014.522_bb0370","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1365-2133.2011.10318.x","article-title":"Contagious itch in humans. A study of visual \"transmission\" of itch in atopic dermatitis and healthy subjects","volume":"164","author":"Papoiu","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1038\/jid.2014.522_bb0375","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0140-6736(12)60642-4","article-title":"Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial","volume":"380","author":"Papp","year":"2012","journal-title":"Lancet"},{"key":"10.1038\/jid.2014.522_bb0380","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000250232","article-title":"Oxatomide in the treatment of chronic urticaria. A double-blind placebo-controlled trial","volume":"162","author":"Peremans","year":"1981","journal-title":"Dermatologica"},{"key":"10.1038\/jid.2014.522_bb0385","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1046\/j.1365-2133.2003.04921.x","article-title":"Randomized, double-blind, placebo-controlled trial of autologous blood therapy for atopic dermatitis","volume":"148","author":"Pittler","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1038\/jid.2014.522_bb0390","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1098\/rstb.2010.0381","article-title":"Placebo mechanisms across different conditions: from the clinical setting to physical performance","volume":"366","author":"Pollo","year":"2011","journal-title":"Philos Trans R Soc London Ser B Biol Sci"},{"key":"10.1038\/jid.2014.522_bb0395","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2133.2007.08236.x","article-title":"Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis","volume":"158","author":"Revicki","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1038\/jid.2014.522_bb0400","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/09546630701646172","article-title":"Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis","volume":"18","author":"Revicki","year":"2007","journal-title":"J Dermatol Treat"},{"key":"10.1038\/jid.2014.522_bb0405","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/clpt.2011.204","article-title":"Mechanisms involved in placebo and nocebo responses and implications for drug trials","volume":"90","author":"Rief","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1038\/jid.2014.522_bb0410","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1046\/j.1365-4362.2001.00186.x","article-title":"Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study","volume":"40","author":"Ring","year":"2001","journal-title":"Int J Dermatol"},{"key":"10.1038\/jid.2014.522_bb0415","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jaci.2011.06.010","article-title":"A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria","volume":"128","author":"Saini","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1038\/jid.2014.522_bb0420","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.iac.2013.09.012","article-title":"Chronic spontaneous urticaria: etiology and pathogenesis","volume":"34","author":"Saini","year":"2014","journal-title":"Immun Allergy Clin North Am"},{"key":"10.1038\/jid.2014.522_bb0425","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1365-2230.2006.02211.x","article-title":"Psychosomatic cofactors and psychiatric comorbidity in patients with chronic itch","volume":"31","author":"Schneider","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"10.1038\/jid.2014.522_bb0430","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000247626","article-title":"Papaverine hydrochloride in the treatment of atopic dermatitis: a double-blind, placebo-controlled crossover clinical trial to reassess safety and efficacy","volume":"183","author":"Shupack","year":"1991","journal-title":"Dermatologica"},{"key":"10.1038\/jid.2014.522_bb0435","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis: Section 3. Management and treatment with phototherapy and systemic agents","volume":"71","author":"Sidbury","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1038\/jid.2014.522_bb0440","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0140-6736(91)90134-B","article-title":"Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis","volume":"338","author":"Sowden","year":"1991","journal-title":"Lancet"},{"key":"10.1038\/jid.2014.522_bb0445","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000319862","article-title":"Prevalence of chronic pruritus in Germany: results of a cross-sectional study in a sample working population of 11 730","volume":"221","author":"St\u00e4nder","year":"2010","journal-title":"Dermatology"},{"key":"10.1038\/jid.2014.522_bb0450","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0190-9622(94)70068-0","article-title":"A double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of thymopentin as an adjunctive treatment in atopic dermatitis","volume":"30","author":"Stiller","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.1038\/jid.2014.522_bb0455","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","article-title":"Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial","volume":"367","author":"Tyring","year":"2006","journal-title":"Lancet"},{"key":"10.1038\/jid.2014.522_bb0460","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2133.1994.tb13111.x","article-title":"Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study","volume":"130","author":"Van Joost","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1038\/jid.2014.522_bb0465","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1016\/j.pain.2011.01.043","article-title":"Induction of nocebo and placebo effects on itch and pain by verbal suggestions","volume":"152","author":"Van Laarhoven","year":"2011","journal-title":"Pain"},{"key":"10.1038\/jid.2014.522_bb0470","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.pain.2009.04.008","article-title":"Factors contributing to large analgesic effects in placebo mechanism studies conducted between 2002 and 2007","volume":"145","author":"Vase","year":"2009","journal-title":"Pain"},{"key":"10.1038\/jid.2014.522_bb0475","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0304-3959(02)00205-1","article-title":"A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia","volume":"99","author":"Vase","year":"2002","journal-title":"Pain"},{"key":"10.1038\/jid.2014.522_bb0480","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1111\/j.1365-2133.2007.07916.x","article-title":"Prevalence of physical symptoms of itch, pain and fatigue in patients with skin diseases in general practice","volume":"156","author":"Verhoeven","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1038\/jid.2014.522_bb0485","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2133.1990.tb14732.x","article-title":"The antipruritic effect of a sedative and a non-sedative antihistamine in atopic dermatitis","volume":"122","author":"Wahlgren","year":"1990","journal-title":"Br J Dermatol"},{"key":"10.1038\/jid.2014.522_bb0490","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2340\/0001555570323329","article-title":"Antipruritic effect of oral cyclosporin A in atopic dermatitis","volume":"70","author":"Wahlgren","year":"1990","journal-title":"Acta Derm Venereol"},{"key":"10.1038\/jid.2014.522_bb0495","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/09546630802607495","article-title":"Efficacy of leukotriene receptor antagonist with an anti-H1 receptor antagonist for treatment of chronic idiopathic urticaria","volume":"20","author":"Wan","year":"2009","journal-title":"J Dermatol Treat"},{"key":"10.1038\/jid.2014.522_bb0500","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2340\/00015555-0662","article-title":"Epidemiology of itch: adding to the burden of skin morbidity","volume":"89","author":"Weisshaar","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"10.1038\/jid.2014.522_bb0505","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/j.1365-2133.2005.06674.x","article-title":"Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial","volume":"152","author":"Wolff","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1038\/jid.2014.522_bb0510","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1136\/ard.2008.092015","article-title":"The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials","volume":"67","author":"Zhang","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1038\/jid.2014.522_bb0515","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1398-9995.2009.02217.x","article-title":"Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study","volume":"65","author":"Zuberbier","year":"2010","journal-title":"Allergy"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X15372237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X15372237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T21:56:42Z","timestamp":1743976602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X15372237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":102,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0022202X15372237"],"URL":"https:\/\/doi.org\/10.1038\/jid.2014.522","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Placebo Effects on Itch: A Meta-Analysis of Clinical Trials of Patients with Dermatological Conditions","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/jid.2014.522","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Society for Investigative Dermatology, Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}